ocular allergy is one of the most frequently encountered conditions in clinical eye care-epidemiologic reports have shown that it affects up to 60 million uS citizens. 1 The eye, being continually exposed to the external environment, is a common site of allergic inflammation. The classic clinical signs of this inflammation are seen in the conjunctiva. allergic conjunctivitis (ac) manifests as a immunoglobulin E (igE) hypersensitivity reaction that occurs when the ocular surface is exposed to external antigens. [2] [3] [4] These antigens include airborne pollen, animal dander, and other environmental antigens. 3, 5 Even though these environmental antigens are not always threats to the ocular surface, they elicit an inappropriate adaptive immune response in some individuals, leading to this hypersensitivity reaction. Sac is most commonly caused due to exposure to pollens from grasses, trees, ragweed, or other seasonal plants. it therefore tends to occur frequently in spring and autumn, which are seasons associated with higher levels of these airborne allergens. 11 While the most obvious solution would be avoidance of the causative agents, this may not always be practical. The most commonly used nonpharmacologic interventions include cold compresses, lubrication, such as artificial tears, and the daily disposal of contact lenses in patients who are wearers. 12 Saline eye drops have been described as effective in reducing signs and symptoms in 30-35 % of cases.
if these options are not successful, multiple pharmacologic treatment modalities are available for Sac, of which antihistamines, mast cell stabilizers, dual-acting mast cell stabilizers-antihistamines, nonsteroidal anti-inflammatory drugs (NSaiDs), and topical ocular corticosteroids are commonly used. these drugs are available in varying doses, act at different levels of the allergic response, and offer different rates of efficacy. while a number of studies address the efficacy or mechanisms of action of individual drugs within these classes, there is a gap in the literature in comparing the efficacy of dual-acting agents to corticosteroids based on mechanism of action. this article reviews the mechanisms of action of antihistamines and mast-cell stabilizers both as stand-alone agents, and as dual-acting mast cell stabilizers-antihistamines and corticosteroids.
The Allergic Inflammatory Response
the allergic inflammatory response occurs in three phases (see Figure 1 ): a sensitization phase, an early phase, and a late phase. 15 the major events that occur in each phase of the reaction are as follows:
Sensitization Phase the sensitization phase occurs when the ocular surface encounters aeroallergens such as pollen. the allergens are processed by antigenpresenting cells (apcs) present on the epithelium of the conjunctival mucosa and presented on the surface of these cells as peptide fragments in association with the major histocompatability complex (mhc) ii molecule. this allergen/mhc activates naïve t helper (t h ) cells, resulting in the maturation of the naïve cells into mature type 2 t h cells, which, in turn, results in the production of cytokines, such as interleukin (il)-4 and il-13, which interact with naïve B cells. antibody switching occurs in these B cells to stimulate the production of ige, which then binds to receptors on the surface of the basophils and mast cells. 15 each mast cell has over a million high affinity receptors, FcεRi for ige.
Early Phase
Upon encountering the same allergen again, the sensitized eye responds by triggering a type i hypersensitivity response, during which the allergen 14 
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binds to mast cell-linked ige antibodies and facilitates the cross-linking of these antibodies. this leads to changes in the outer surface of the mast cell, making it more permeable to calcium ions. the crosslinking of a critical mass of ige antibodies causes the mast cells to degranulate and release a variety of primary inflammatory mediators that are stored in their preformed granules. these include histamine, serotonin, lipid-derived mediators, such as leukotrienes c4, D4, and e4 and prostaglandins D2 and e2, platelet-activating factor, proteases such as tryptase and chymase, heparin, and other eosinophil and neutrophil chemoattractants. 15 histamine, the classic mediator of allergic inflammation, is a primary amine that plays a pivotal role in the pathogenesis of all allergic diseases. it is released from mast cells and basophils after a specific allergen binds to the ige present on the cell surface. it binds to specific receptors and stimulates the increased release of multiple proinflammatory cytokines and arachidonic acid metabolites, resulting in a vasoactive effect. 4 delivery to provide rapid action combined with ocular surface hydration. 4 Because histamine is a major contributor to the signs and symptoms of the immediate reaction, topical antihistamines play an important role in providing symptomatic relief. has also shown better efficacy than sodium cromoglycate, antazoline/ naphazoline, and oral terfenadine. 24 ac may be accompanied by rhinitis (rhinoconjunctivitis); in these cases, oral or nasal antihistamines may be prescribed. however, systemic
antihistamines are reported to produce side effects such as ocular surface damage from decreased tear volume and tear flow and sedation. 25, 26 Despite the advancements in drug delivery and receptor action, antihistamines are still unable to block all manifestations of allergic inflammation because histamine is not the only mediator released by mast cells during the allergic response. Other mast cell-derived mediators such as proteases, lipid-derived mediators, and cytokines also initiate a cascade of events that culminates in conjunctival vasodilation, increased conjunctival vascular permeability, and migration and infiltration of inflammatory leukocytes to the ocular surface. 16 Because the mast cell is the primary site of release of these mediators, an alternative therapeutic approach was adopted, resulting in the development of a drug class known as mast cell stabilizers.
Mechanisms of Action of Mast Cell Stabilizers in Ocular Allergy
the mast cell is pivotal in the inflammatory cascade in allergic eye disease. inhibition of mast cell degranulation is an important target for reducing the acute symptoms of the active disease. 27 mast cell stabilizers offer sustained and prolonged efficacy, possibly via the inhibition of mast cell cytokinemediated events on proximal cells such as the upregulation and expression of adhesion molecules and ocular epithelial cell-mediated chemokine release. 16 mast cell stabilizers were initially thought to inhibit mast cell degranulation by inhibiting calcium influx; further research has suggested they may also act by inhibiting eosinophil, neutrophil, and monocyte activation as well as blocking the release of pro-inflammatory cytokines from inflammatory cells. 28 By preventing the degranulation of mast cells and the release of preformed and additional newly formed mediators, they potentially impact both the early-and late-phase reactions. 8 common mast cell stabilizers such as lodoxamide, cromolyn sodium, and nedocromil sodium have proven efficacy in the treatment of Sac. [29] [30] [31] [32] [33] while all mast cell stabilizers reduce hyperemia, itching, and irritation, they may vary in their efficacy in relieving such signs and symptoms of Sac. 8, 34 mast cell stabilizers offer the theoretical advantage of inhibiting the release of all mediators at the cellular level; however, they may not completely inhibit all mast cell-mediated reactions. Further, in some circumstances, they may not be as effective as antihistamines for symptomatic relief as their onset of action is relatively slow and complete effects may not be seen for up to 3 weeks. 35 in a comprehensive review of ocular allergic disease, Bhargava et al. state that given their mechanism of action, mast cell stabilizers would be most effective given prophylactically. 36 this is attributed to the need for stabilization of mast cells prior to the degranulation triggered by the allergic reaction; they require a long loading period and must therefore be applied routinely for several weeks before expected exposure for optimal benefit-this may lead to decreased patient compliance.
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Mechanism of Action of Dual-Acting Agents in Ocular Allergy
pure antihistamines and mast cell stabilizers have limitations when prescribed alone-antihistamines target h1 receptor-specific activity, while mast cell stabilizers have a slow onset of action and work best prophylactically. Dual-acting mast cell stabilizers-antihistamines, however, provide both mast cell stabilizing and antihistaminic activity and are therefore more commonly used in the treatment of signs and symptoms of Sac. these drugs work by stabilizing mast cells and antagonizing the h1 receptor; thus, the mast cell stabilizing action provides an added benefit over pure antihistamines. 12 this dual-acting class includes drugs such as bepotastine, azelastine, epinastine, ketotifen, alcaftadine, and olopatadine (see Figure 2 ).
phase iii trials of bepotastine 1.5 % solution have demonstrated its efficacy and tolerability in the treatment of the signs and symptoms associated with ac. 37, 38 pooled data from these two placebo-controlled, conjunctival allergen challenge (cac) trials that randomized 157 patients to receive either bepotastine (n=78) or placebo (n=79) were also analyzed. 39 Ocular itching, the primary efficacy measure, was significantly reduced in all patients receiving bepotastine compared with those receiving placebo (p<0.0001 for all time points). Furthermore, the reported adverse events in both trials were generally mild-with no patient experiencing a serious or severe adverse event, and no event considered related to the drug.
after a cac, bepotastine 1.5 % solution produced statistically significant reductions in individual nonocular symptoms including nasal congestion, are less precise and results may be confounded due to high variability in pollen levels, subject exposure time to the environment, and patient study medication compliance.
Ketotifen, a benzocycloheptathiophene agent, has been approved in the US for the treatment of ocular itching associated with ac. 43 it is a noncompetitive, h1 receptor antagonist with multiple mechanisms of action: it stabilizes mast cells, inhibits platelet activating factor, and serves as an eosinophil inhibitor. while ketotifen has no effect on serotonin 5ht, adrenergic, or dopaminergic receptors, it has demonstrated a direct inhibitory effect on eosinophil oxidative metabolism. 44, 45 in a study comparing the efficacy and safety of ketotifen 0.025 % to that of levocabastine 0.05 % in the treatment of Sac, 519 patients with Sac were randomly assigned to ketotifen, placebo, or levocabastine twice daily in each eye for 4 weeks. patients were assessed at follow up (days 5-8) and end of study (days 25-31) visits. 46 the responder rate, based on the subjects' assessment of global efficacy at the follow-up visit, was the primary efficacy variable. Ketotifen produced significantly better outcomes than levocabastine for relief of the signs and symptoms of Sac at both the follow-up and termination visits (p<0.05).
Olopatadine, another dual-acting mast cell stabilizer-antihistamine, has been approved by the US Food and Drug administration (FDa) for the treatment of the signs and symptoms of ac. the safety and efficacy of olopatadine has been shown in active-and placebo-controlled trials. [47] [48] [49] the efficacy of olopatadine 0.1 % was compared with levocabastine 0.05 % in a cac study. 50 Subjects were bilaterally challenged with an allergen 27 minutes after topical drug administration, and the first postchallenge assessment was carried out 3 minutes later, or 30 minutes after instillation of the drug. Ocular symptoms were graded on a standard 0-4 scale. Ocular itching severity for olopatadine 0.1 % was significantly lower than that for levocabastine 0.05 % at 3 minutes and 10 minutes post-challenge (p<0.001). Further, grading of ocular redness severity significantly favored olopatadine (p<0.0001). Olopatadine has also been shown to demonstrate statistically significant improvement compared with epinastine in a study using the cac model. 47 in a placebo-controlled cac study evaluating the efficacy of olopatadine 0.2 % in reducing the signs and symptoms of ac in 90 patients, 49 olopatadine 0.2 % was found to be significantly more effective than placebo in the treatment of ocular itching at 15 minutes and 16 hours (p<0.001 for both). a 10-week, randomized, placebo-controlled trial to determine the efficacy and safety of 0.2 % olopatadine QD in the treatment of ac or rhinoconjunctivitis was conducted in 260 patients. 48 this environmental study assessed ocular signs and symptoms in terms of frequency (whole-unit scale from 0 to 5) and severity (half-unit scale from 0 to 4); grass pollen counts were also assessed daily. analyses of ocular itching and redness showed that when grass pollen counts were high, a respective 21 % and 14 % of patients in the olopatadine 0.2 % group assessed the frequency of ocular itching and redness as >grade 2 compared with 47 % and 31 % of patients in the placebo group (p<0.001 for ocular itching; p<0.003 for redness, respectively).
the FDa approved alcaftadine 0.25 % in 2011 as a dual-action agent for the prevention of itching associated with ac. in a phase iv double-masked, placebo, and active controlled head-to-head cac study, alcaftadine 0.25% was compared with olopatadine 0.2 %. the primary efficacy measure was ocular itching evaluated by the subject at 3, 5, and 7 minutes post-challenge. an inactive metabolite is first converted into an isosteric/isoelectronic analog with structural modifications. after eliciting the desired therapeutic effect, this analog undergoes rapid, predictable metabolism back to the original inactive metabolite. 62 Because of this retrometabolic design, le has several advantages over the c-20 ketone-based corticosteroids.
le is rapidly converted into its inactive metabolites by circulating esterases after exerting its therapeutic effect, resulting in fewer ocular side effects than older c-20 corticosteroids such as prednisolone (see Figure   3 ). 63 this unique metabolic profile is particularly important, as numerous studies have shown that le use results in fewer clinically significant increases in iOp. 14, 64, 65 cataract formation is another concern associated with extended corticosteroid use. corticosteroid-induced cataract formation occurs due to nonenzymatic formation of Schiff base intermediates between the steroid c-20 ketone group and nucleophilic groups, such as ε-amino groups of lysine residues of lens proteins. this Schiff base formation is followed by a heyns rearrangement of the adjacent c-21 hydroxyl group, resulting in stable anime-substituted adducts. 61 Similar results were observed for the investigator global assessment (86 % versus 64 %; p< 0.001) and the secondary composite evaluation (77 % versus 68 %), although the differences for the secondary composite signs and symptoms evaluation were not statistically significant (p=0.092).
None of the le-treated patients had an increase in iOp of ≥10 mm hg, whereas two placebo patients did experience such an increase. Results from these trials suggested that 0.5 % le was safe and more efficacious than placebo in the treatment of Sac. acting mast cell stabilizer-antihistamines are preferred, and studies have shown they are more effective than either agent is alone. corticosteroids exert effects on the entire inflammatory cascade, and are the most potent option available for the treatment of the signs and symptoms associated with Sac. Some clinicians reserve the use of corticosteroids for severe allergy owing to concerns about their potential to increase iOp. le, a c-20 ester corticosteroid, provides similar potency to that of ketone corticosteroids with less effect on iOp. in one currently published environmental study, le offered better efficacy than the dual-acting agent olopatadine. 68 Further comparative studies are warranted.
Despite the wide range of treatments available, it is difficult to identify which drug or drug class is superior to another due to differences in study designs and outcome measures. however, we conclude that compared with antihistamine-mast cell stabilizer agents, corticosteroids produce a more comprehensive inhibition of the allergic inflammatory cascade. the c-20
ester structure of le minimizes the potential for the ocular side effects of most concern-increased iOp and c ataract formation-and therefore may be a better choice. Finally, preliminary results from studies with SeGRas are promising and suggest that these molecules may emerge as the treatment of choice for ac; however, data from large multicenter trials are awaited. n
